Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Roctavian
Pharma
BioMarin unveils strategic redesign under CEO Alexander Hardy
The company's game plan includes five new indications for dwarfism drug Voxzogo through 2031, which could represent a $5 billion opportunity.
Zoey Becker
Sep 4, 2024 5:32pm
BioMarin lays off 225 more staffers under new corporate strategy
Aug 29, 2024 4:30am
BioMarin downsizes gene therapy efforts to focus on 3 markets
Aug 6, 2024 10:34am
With slow sales, BioMarin weighs Roctavian divestiture
Apr 29, 2024 11:51am
BioMarin’s commercial chief Jeffrey Ajer hits the exit
Jan 12, 2024 10:28am
JPM24: New BioMarin CEO Hardy makes his priorities clear
Jan 10, 2024 11:29am
